STOCKS TELEGRAPH

Tag: Ensysce Biosciences

  • Ensysce (ENSC) Stock Sees Market Uplift Following New Patent Approval

    Ensysce (ENSC) Stock Sees Market Uplift Following New Patent Approval

    The market observed a sharp increase in Ensysce Biosciences, Inc. (NASDAQ: ENSC) shares after the company revealed a noteworthy intellectual property milestone. The stock of ENSC was up 81.28% on the charts at $3.39 as of the most recent trading update.

    Patent Approved for Novel Treatment of Opioid Use Disorder

    Following Ensysce’s receipt of a Notice of Allowance from the U.S. invention and Trademark Office for its invention entitled “Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof,” investor confidence has surged. The formulation and method of use claims for its innovative therapeutic drug, PF9001, are covered by this patent.

    PF9001, which was created using Ensysce’s own TAAP (Trypsin Activated Abuse Protection) and MPAR (Multi-Pill Abuse Resistance) platforms, is a novel strategy for combating the continuing opioid crisis.

    A Safer Substitute for Conventional Methadone Treatment

    Despite being commonly used to treat opioid use disorder (OUD), methadone has come under fire for probable overdose, respiratory depression, and heart problems. With its targeted release mechanism, which provides overdose protection and a consistent, once-daily dosage profile, PF9001 seeks to lessen these risks. Early data suggests a significant reduction in cardiotoxicity risks, bolstering the credibility of Ensysce’s overdose prevention technology.

    Expert Endorsement and Institutional Support

    The significance of such breakthroughs was emphasized by Dr. Richard Dart, the director of the Rocky Mountain Poison and Drug Center and a renowned expert in toxicology and emergency care. He pointed out that by lowering the risk of overdose, the use of MPAR technology with methadone analogs may save lives.

    Path Forward with Federal Backing

    Extensive research efforts to improve treatment results for OUD patients led to the creation of PF9001. The National Institute on Drug Abuse (NIDA) has acknowledged the initiative and provided funding, confirming its potential to improve public health. In the battle against opioid dependence, Ensysce (ENSC) thinks PF9001 might greatly increase patient compliance and yield better treatment outcomes.

  • After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest

    After-Hour Gains For Ensysce Biosciences (ENSC) Signal Renewed Interest

    After-hours trading on Thursday saw a partial recovery for Ensysce Biosciences, Inc. (NASDAQ: ENSC), reducing the market volatility that had been caused by a major equities release earlier in the day. In the extended session, shares of ENSC increased 7.86% to settle at $2.47 after dropping 13.26% during normal trading hours.

    New Capital via Private and Registered Offerings

    Ensysce Biosciences said that it had signed definitive agreements to generate around $1.1 million in gross revenue. ENSC will issue and sell 315,188 shares of its ordinary stock at a price of $3.49 per share through a registered direct offering priced at-the-market. In tandem, the company will conduct a private placement involving the issuance of unregistered Series A-5 and Series A-6 warrants, each allowing the purchase of up to 315,188 shares.

    At a price of $3.24 per share, the Series A-5 and A-6 warrants will be immediately exercisable. The Series A-6 warrants will be valid for five years, whilst the Series A-5 warrants will be valid for eighteen months. Depending on normal closing circumstances, the offering is anticipated to close on or around March 31, 2025. The offering’s proceeds will be used for general working capital and the advancement of Ensysce Biosciences’ exclusive TAAP and MPAR projects.

    PAINWeek 2025 Preparations

    As part of its efforts to strengthen its clinical and scientific presence, Ensysce Biosciences announced that on September 3, 2025, at PAINWeek 2025, it would host a symposium. The event’s goal is to further the discussion on pain management and the future of analgesic treatments.

    New Developments in Pain Management

    As part of the symposium preparations, ENSC recently held a panel discussion titled “The State of the Nation in Pain: A Discussion on Analgesics and Their Optimal Uses.” The panel covered new advances including Ensysce Biosciences’ PF614, a next-generation opioid, as well as the therapeutic value of presently existing analgesics and advancements in pain treatment. ENSC remains committed to collaborating with medical professionals as it creates a new class of pain treatment.

  • Ensysce Biosciences, Inc. (ENSC) Stock Surged 21.45% Pre-Market, Here’s Why              

    Ensysce Biosciences, Inc. (ENSC) stock surged 21.45% in the pre-market trading session at the price of $1.84 after announcing its earnings report for the third quarter of 2021.  

    Ensysce Biosciences is a clinical-stage biotechnology firm that develops tamper-proof opioids to control overdoses and drug abuse. The company uses its Multi-Pill Abuse Resistance and Trypsin-Activated Abuse Protection platforms to produce safer prescription drugs.  

    ENSC Third Quarter 2021 Financial Results  

    On 15th November 2021, ENSC reported its financial results for the third quarter ended 30th September 2021 and presented corporate updates.  

    Financial Highlights  

    ENSC reported a net loss of $17.2 million for the third quarter of 2021. For the same period in 2020, net income was $1.6 million. The company acquired $10 million in funding from the convertible note financing on 5th November 2021. For the third quarter of 2021, funding under federal grants totaled $1.2 million. Funding under federal grants was $0.8 million for the same quarter of the previous year.  

    ENSC reported research and development costs of roughly $1.7 million for the third quarter ended 30th September 2021. R&D expenses were $0.9 million for the three months ended on 30th September of 2020. For the third quarter of 2021, general and administrative costs totaled $16.4 million. G&A expenses were approximately $0.3 million for last year’s same quarter. As of 30th September 2021, ENSC reported cash and cash equivalents of roughly $6.8 million. 

    Completion of Convertible Note Financing 

    On 8th November 2021, ENSC published the completion of its private placement for senior secured convertible notes for an aggregate investment of $15 million. The company will use total gross proceeds worth $15 million for its general working capital plans. The first closing provided $5 millions of funding on 24th September 2021. On 5th November 2021, the second closing provided $10 million of funding.  

    The Notes are exchangeable into common stock shares at a conversion price of $5.87. The Notes had issued with an original discount of 6%. The Warrants have the right to purchase common stock shares at an exercise price of $7.63 and are exercisable for five years after the issuance.  

  • Ensysce Biosciences, Inc. (ENSC) stock has fallen in aftermarket – Here’s why?

    Ensysce Biosciences, Inc. (ENSC) has experienced a decline of 0.42% in the aftermarket. However, the last trading session closed at $2.37 with a decrease of 4.44%.

    $15 Million Convertible Note Financing

    ENSC announced $15 Million Convertible Note Financing on 27th September 2021. ENSC stated that it has committed to a securities purchase agreement with institutional investors. Prior to fees and selling expenditures, the Investors provided initial financing of $5 million on September 24, 2021.

    The Notes are transferable into ENSC common stock at a conversion price of $5.87. This is a 30% premium to the initial closing price. Moreover, the Notes will mature 21 months after the applicable closing date. It will bear interest at a rate of 5.0 percent per year from the day of issuance. This will be applicable with monthly principal payments in cash or common stock commencing roughly 90 days after the original closure. The Notes had a 6% discount when they were first released. The Warrants offer the option to buy up to 361,158 shares of common stock for $7.63 each, a 30% premium to the conversion price. Lastly, the Warrants have a five-year expiration date.

    About ENSC

    ENSC is a biotech firm dedicated to combating the scourge of prescription medication addiction. Their unique prodrug technologies, abuse-resistant TAAP, and overdose-resistant MPAR are designed to improve the treatment of chronic pain patients while lowering the human and financial consequences of prescription drug misuse.

    ENSC Products & Clinical Programs

    The TAAP platform, developed by ENSC, is a patented abuse-resistant prodrug technology that aims to enhance patient care while lowering the human and financial costs of prescription drug misuse. When exposed to simple extraction, TAAP efficiently resists chewing, crushing, injection, and inhalation. Not only does our TAAP technology function with all known opioids, but it also works with most medicines that have the potential, such as ADHD meds. Our TAAP medicines are in a competitive environment. This has given the rising desire of various government agencies, including the FDA, to shift to more abuse-resistant opioid treatments. MPAR is a first-of-its-kind product in the market, developed not just to combat addiction but also to save lives by avoiding overdose.